Basilea announces CHF 75 million senior secured loan agreement with Athyrium for non-dilutive refinancing of convertible bonds due in December 2022
Ad hoc announcement pursuant to Art. 53 LR
Basel/Allschwil, Switzerland, September 07, 2022
Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that is has entered into a senior secured loan agreement with funds managed by Athyrium Capital Management, LP ("Athyrium"). The CHF 75 million senior secured loan will be used by Basilea for the repayment of its convertible bonds (ISIN CH0305398148), which are due in December 2022 in an outstanding nominal amount of approximately CHF 117 million.
Adesh Kaul, Chief Financial Officer of Basilea, said: “We are pleased to have secured this non-dilutive refinancing of our outstanding 2022 convertible bonds. The transaction allows us to achieve our goals of both reducing our debt level and avoiding dilution for our shareholders. Based on our strong financial position and growth prospects, we will be able to pay the remainder of the outstanding amount of the 2022 convertible bonds with cash at hand and furthermore, we intend to repay the CHF 75 million senior secured loan within two years from cash flows expected to be generated from our growing commercial business.”
Laurent D. Hermouet, Partner at Athyrium, added: “We are excited to work with Basilea to support its anti-infectives strategy. Basilea has demonstrated strong capabilities in the development, partnering and commercialization of anti-infectives and we look forward to the continued advancement of its pipeline candidates.”
The senior secured loan has a two-year term and repayment is expected to start as of Q1 2023 on a quarterly basis. Interest payments, excluding fees, are expected to amount to an average of approximately CHF 1.25 million per quarter over the term. The transaction is subject to customary closing conditions.
The transaction has no impact on Basilea’s financial guidance for 2022.
About Athyrium Capital Management
Athyrium is a specialized asset management company formed in 2008 to focus on investment opportunities in the global healthcare sector. Athyrium advises funds with over $4.6 billion in committed capital. The Athyrium team has substantial investment experience across a wide range of asset classes including public equity, private equity, fixed income, royalties, and other structured securities. Athyrium invests across all healthcare verticals including biopharma, medical devices and products, healthcare focused services, and healthcare information technology. The team partners with management teams to implement creative financing solutions to companies’ capital needs. For more information, please visit www.athyrium.com.
Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. In addition, we have several preclinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.
This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
|Peer Nils Schröder, PhD|
Head of Corporate Communications & Investor Relations
Basilea Pharmaceutica International Ltd, Allschwil
|Phone||+41 61 606 1102|
This ad hoc announcement can be downloaded from www.basilea.com.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
EPH European Property Holdings PLC - Notice of Extraordinary General Meeting7.10.2022 19:00:00 CEST | Press release
7 October 2022, Nicosia, Cyprus I Ad hoc announcement pursuant to Art. 53 LR NOTICE IS HEREBY GIVEN THAT an Extraordinary General Meeting of EPH EUROPEAN PROPERTY HOLDINGS PLC (the “Company” or “EPH”) will be held on 1st November 2022 at 11 AM at Hotel Four Seasons Hotel Limassol, 67-69 Amathountos Avenue, Ag. Tychonas, 4532 Limassol, Cyprus, FOR THE FOLLOWING PURPOSES: APPROVAL OF SALE OF EPH GROUPS’ RUSSIAN PORTFOLIO The uncertainty over the future economic and political developments as well as the Russian economy have led the Board of Directors to the conclusion to ask the Company’s shareholders for approval of the sale of the entire Russian property portfolio within the framework of a management buy-out. The sale involves six rental properties and Arbat apartments in Moscow together with their holding companies domiciled in Cyprus and Germany, which account for around 40% of EPH’s total asset value. The basis for the purchase price consideration will be the market values of the Rus
Nordic American Tankers Ltd (NYSE: NAT) – 2022 Annual General Meeting of Shareholders (AGM)7.10.2022 14:30:00 CEST | Press release
Friday, October 7, 2022 Dear Shareholders and Investors, In our press release of June 7, 2022, we informed you about the date of the 2022 Annual General Meeting (AGM) in Nordic American Tankers Limited (NAT). The date has been set to November 17, 2022. Please be informed that the record date is September 26, 2022, for the determination of the NAT shareholders entitled to receive notice of and to vote at the AGM or any adjournment thereof. The Notice of the Meeting and Proxy Statement will be available with the Securities and Exchange Commission (SEC) on a form 6-K today, October 7, 2022. The AGM will take place in Monaco. For contacts, please see at the end of this communication. Best regards, Herbjorn Hansson Founder, Chairman & CEO Nordic American Tankers Ltd. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections
The order to supply all mineral processing technologies for ShalkiyaZinc’s greenfield zinc-lead concentrator in Kazakhstan becomes effective7.10.2022 14:27:54 CEST | Press release
COMPANY ANNOUNCEMENT NO. 16-2022 The previously announced signed contract to supply all mineral processing technology to ShalkiyaZinc, the operator of a zinc and lead mine in the Kyzylorda Region, located in the south of Kazakhstan (refer to Company Announcement No. 12-2022), is now effective. The contract is valued at around DKK 950 million and will be part of the Q4 2022 order intake. The equipment delivery is to be completed during 2024, with commissioning to start before the end of that year. The new plant will be a world-class production facility that efficiently separates the minerals with a minimised environmental impact. As detailed in the order announcement in August 2022, FLSmidth will supply two underground crushing stations with a materials handling system to the process plant, a full package of comminution and separation equipment. This includes SAG and ball mills, mill circuit pumps and cyclones, the zinc-lead concentrate flotation and regrinding circuit, including nextST
Program for the publication of Yara International ASA third quarter results 20227.10.2022 11:05:00 CEST | Press release
The Yara International ASA third quarter 2022 results will be published on Thursday20October 2022at08:00 CEST. An on-line presentation will be held at 12:00 CEST, hosted by Yara President and CEO Svein Tore Holsether. The presentation will be held in English. The report, presentation and webcast will be available at the above mentioned times at: yara.com/investor-relations/latest-quarterly-report/ There will also be a conference call at 13:00 CEST the same day with an opportunity to ask questions to Yara’s management. Please use this link to register for this session: https://registrations.events/direct/Q4E60136. Registered participants will receive a full list of available international dial-in numbers and a unique passcode upon completed registration. Please join the event 5-10 minutes prior to scheduled start time. Alternatively, it is possible to use the dial-in numbers listed below on the day of the conference call to register through an operator: Norway - National +18.104.22.168.30
Telenor etablerer fiberselskap i Norge7.10.2022 08:55:29 CEST | Pressemelding
(Fornebu 07 september 2022) Telenor inngår en transaksjon som skal støtte fremtidige investeringer i Norges telekominfrastruktur. Tidligere i år påbegynte Telenor en prosess for å vurdere etableringen av et eierselskap for passiv fiberinfrastruktur, med en medinvestor i en minoritetsposisjon. Telenor har nå kommet til enighet om å selge 30 prosent av det nye fiberselskapet til et konsortium ledet av det globale investeringsselskapet KKR, som investerer gjennom sin kjerneinfrastrukturstrategi. Konsortiet inkluderer Oslo Pensjonsforsikring som medinvestor. Det nyetablerte selskapet er et datterselskap av Telenor og vil bli en del av det nye forretningsområdet Telenor Infrastruktur. Selskapet vil eie de passive elementene i det norske fibernettet. Dette omfatter omtrent 130.000 kilometer med kabler som leverer tjenester til omtrent 560.000 husstander. Eiendelene vil bli skilt ut fra Telenor Norge før transaksjonen sluttføres. Telenor Norge blir selskapets eneste kunde og alle operasjonell